Final results from IMPROVE: A randomized, controlled, open-label, cross-over phase IV study to determine the patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab for advanced HR+/HER2- breast cancer.

Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Rieger L, Chiabudini M, Falkenstein J, Runkel E, Potthoff K., 2018.

Oncol Res Treat 41 (suppl 4)(P916).